Evidence map›Paper›PMID 30465164›Full record

ArticleJournal of thrombosis and thrombolysis2019

Combination index of the concentration and in vivo antagonism activity of racemic warfarin and its metabolites to assess individual drug responses.

Shuhei Kobayashi, Koji Ishii, Yasuko Yamada, Emi Ryu, Junya Hashizume, Seiichi Nose, Tetsuya Hara, Mikiro Nakashima, Kaname Ohyama

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Shuhei KobayashiSchool of Pharmaceutical Sciences, Nagasaki University, Nagasaki, Japan.
Koji IshiiDepartment of Anesthesiology, Nagasaki University School of Medicine, Nagasaki, Japan.
Yasuko YamadaAnalytical and Quality Evaluation Research Laboratories, Daiichi Sankyo Co., Ltd., Hiratsuka, Japan.
Emi RyuDepartment of Pharmacy, Nagasaki University Hospital, Nagasaki, Japan.
Junya HashizumeDepartment of Pharmacy, Nagasaki University Hospital, Nagasaki, Japan.
Seiichi NoseDepartment of Pharmacy, Nagasaki University Hospital, Nagasaki, Japan.
Tetsuya HaraDepartment of Anesthesiology, Nagasaki University School of Medicine, Nagasaki, Japan.
Mikiro NakashimaUnit of Medical Pharmacy, Department of Pharmacy Practice, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto-machi, Nagasaki, 852-8588, Japan.
Kaname OhyamaUnit of Medical Pharmacy, Department of Pharmacy Practice, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto-machi, Nagasaki, 852-8588, Japan. k-ohyama@nagasaki-u.ac.jp.ORCID http://orcid.org/0000-0002-1449-5505
Nagasaki University · JPNagasaki University Hospital · JPDaiichi-Sankyo (Japan) · JP

Funding

the Ministry of Education, Culture, Sports, Science and Technology of Japan 18K15393
6 · The paper itself

Abstract

The present study was undertaken to examine whether in vivo vitamin K epoxide reductase complex 1 (VKOR) "actual" antagonism activity, calculated by the concentrations and the reported anticoagulant activities of the R- and S-warfarin enantiomers and their metabolites, correlates with the weekly dose of warfarin. Five patients under palliative care were enrolled in our study and 20 serum samples were analyzed by an enantioselective high-performance liquid chromatography-ultraviolet detection method. In vivo VKOR inhibition activities of S-warfarin, R-warfarin, 7- and 10-hydroxywarfarin were calculated as the ratio of drug or metabolite concentration to the IC

Indexed as

Blood Specimen CollectionChromatography, High Pressure LiquidDrug MonitoringFemaleHumansInternational Normalized RatioMaleMiddle AgedStereoisomerismVitamin K Epoxide ReductasesWarfarin10-hydroxywarfarin7-hydroxywarfarinVitamin K Epoxide ReductasesVKORC1 protein, humanWarfarinEnantiomerHydroxylated warfarinIn vivo antagonism activityPhenotypingWarfarin

Identifiers

PMID30465164
OpenAlexW2901238952

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.